References

Anscombe, F.J. (1963). "Sequential medical trials." Journal of the American Statistical Association. 58, 365–383.

Armitage, P. (1975). Sequential Medical Trials. Second edition. London: Blackwell Scientific Publications.

Bather, J. (2000). Decision Theory: an Introduction to Dynamic Programming and Sequential Decisions. Chichester: Wiley.

Berger, J.O. (1985). Statistical Decision Theory and Bayesian Analysis. Second edition. New York: Springer-Verlag.

Bergman, S.W., Gittins, J.C. (1985). Statistical Methods for Pharmaceutical Research Planning. New York: Marcel Dekker.

Berry, D.A., Mueller, P., Grieve, A.P., Smith, M., Parke, T., Blazek, R., Mitchard, N., Krams, M. (2000). "Adaptive Bayesian Designs for Dose-Ranging Drug Trials." In Case Studies in Bayesian Statistics V. C. Gatsonis, R. E. Kass, B. Carlin, A. Carriquiry, A. Gelman, I. Verdinelli and M. West, eds. New York: Springer-Verlag. 99–181

Bertolli, J., Hu, D.J., Nieburg, P., Macalalad, A., Simonds, R.J. (2003). "Decision analysis to guide choice of interventions to reduce mother-to-child transmission of HIV." AIDS. 17, 2089–2098.

Brown, M.M., Brown, G.C., Sharma, S., Landy, J. (2003). "Health care economic analyses and value-based medicine." Survey of Ophthalmology. 48, 204–223.

Burman, C.-F., Hamrén, B.,Olsson, P. (2005). "Modelling and simulation to improve decision-making in clinical development." Pharmaceutical Statistics. 4, 47–58.

Burman, C.-F., Senn, S. (2003). "Examples of option values in drug development." Pharmaceutical Statistics. 2, 113–125.

Carlin, B.P., Kadane, J.B., Gelfand, A.E. (1998). "Approaches for optimal sequential decision analysis in clinical trials." Biometrics. 54, 964–975.

Claxton, K., Posnett, J. (1996). "An economic approach to clinical trial design and research priority-setting." Health Economics. 5, 513–524.

Cooper, N.J., Sutton, A.J., Abrams, K.R. (2002). "Decision analytic economic modelling within a Bayesian framework: application to prophylactic antibiotics use for Caesarean section." Statistical Methods in Medical Research. 11, 491–512.

Cornfield, J. (1969). "Sequential trials, sequential analysis and the likelihood principle." The American Statistician. 20, 18–22.

Darken, P.F., Ho, S.-Y. (2004). "A note on sample size savings with the use of a single well-controlled clinical trial to support the efficacy of a new drug." Pharmaceutical Statistics. 3, 61–63.

DiMasi, J.A., Hansen, R.W., Grabowski, H.G. (2003). "The price of innovation: new estimates of drug development costs." Journal of Health Economics. 22, 151–185.

Dixit, A.K., Pyndick, R.S. (1994). Investment under uncertainty. Princeton: Princeton University Press.

Elwyn, G., Edwards, A., Eccles, M., Rovner, D. (2001). "Decision analysis in patient care." The Lancet. 358, 571–574.

FDA (U.S. Department of Health and Human Services. Food and Drug Administration) (1998). Guidance for industry: Providing clinical evidence of effectiveness for human drug and biological products." http://www.fda.gov/cder/guidance/1397fnl.pdf.

FDA (U.S. Department of Health and Human Services. Food and Drug Administration) (2004). "Challenge and opportunity on the critical path to new medical products." http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html.

FDA (U.S. Department of Health and Human Services. Food and Drug Administration) (2006). "Critical Path Opportunities List." http://www.fda.gov/oc/initiatives/criticalpath/reports/opp list.pdf.

Fisher, L.D. (1999). "One large, well-designed, multicenter study as an alternative to the usual FDA paradigm." Drug Information Journal. 33, 265–271.

Freedman, L.S., Spiegelhalter, D.J.(1989). "Comparison of Bayesian with group sequential methods for monitoring clinical trials." Controlled Clinical Trials. 10, 357–367.

French, S (1989). Readings in Decision Analysis. London: Chapman and Hall.

French, S., Ríos Insua, D. (2000). Statistical Decision Theory. London: Arnold.

Gittins, J. and Pezeshk, H. (2000). "A behavioral Bayes method for determining the size of a clinical trial." Drug Information Journal. 34, 355–363.

Graham, G., Gupta, S., Aarons, L. (2002). "Determination of an optimal regimen using a Bayesian decision analysis of efficacy and adverse effect data." Journal of Pharmacokinetics and Pharmacodynamics. 29, 67–88.

Howard, R.A., Matheson, J.E. eds. (1984). The Principles and Applications of Decision Analysis. Part I-II, Menlo Park, CA: Strategic Decision Group.

Kadane, J.B., Vlachos, P.K. (2002). "Hybrid methods for calculating optimal few-stage sequential strategies: data monitoring for a clinical trial." Statistics and Computing. 12, 147–152.

Lehmann, E. L. (1986). Testing Statistical Hypothesis, New York: Wiley.

Lindley, D. V. (1997). "The choice of sample size." The Statistician. 46, 129–138.

Liu, J.Y., Finlayson, S.R.G., Laycock, W.S., Rothstein, R.L., Trus, T.L., Pohl, H., and Birkmeyer, J.D. (2003). "Determining an appropriate threshold for referral to surgery for gastroesophageal reflux disease." Surgery. 133, 5–12.

O'Hagan, A., Stevens, J. (2001). "Bayesian assessment of sample size for clinical trials of cost-effectiveness." Medical Decision Making. 21, 219–230.

Pallay, A. (2000). "A decision analytic approach to determining sample sizes in a Phase III program." Drug Information Journal. 34, 365–377.

Pallay, A., Berry, S.M. (1999). "A decision analysis for an end of Phase II go/stop decision." Drug Information Journal. 33, 821–833.

Parmigiani, G. (2002). Modeling in Medical Decision Making. New York: Wiley.

Pearson, A.W. (1972). "The use of ranking formulae in R & D projects." R & D Management. 2, 69–73.

Pezeshk, H. (2003). "Bayesian techniques for sample size determination in clinical trials: a short review." Statistical Methods in Medical Research. 12, 489–504.

Poland, B., Wada, R. (2001). "Combining drug-disease and economic modelling to inform drug development decisions." Drug Discovery Today. 6, 1165–1170.

Protheroe, J., Fahey, T., Montgomery, A.A., Peters, T.J., Smeeth, L. (2000). "The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis." British Medical Journal. 320, 1380–1384.

Raiffa, H. (1968). Decision Analysis—Introductory Lectures on Choices under Uncertainty, Reprinted 1997, New York: McGraw Hill.

Raiffa, H., Schlaifer, R. (1961). Applied Statistical Decision Theory. Reprinted 2000, New York: Wiley.

Rosenkranz, G. (2002). "Is it possible to claim efficacy if one of two trials is significant while the other just shows a trend?" Drug Information Journal. 36, 875–879.

Savage, L.J. (1954). The Foundations of Statistics. New York: Wiley.

Senn, S.J. (1996). "Some statistical issues in project prioritisation in the pharmaceutical industry." Statistics in Medicine. 15, 2669–2702.

Senn, S.J. (1997). Statistical Issues in Drug Development. Chichester: Wiley.

Senn, S.J. (1998). "Further statistical issues in project prioritisation in the pharmaceutical industry." Drug Information Journal. 32, 253–259.

Senn, S.J., Rosati, N. (2002). "Project selection, decision analysis and profitability in the pharmaceutical industry." Business Briefing: Pharmatech 2002. 18–21, London. http://www.wma.net/e/publications/pdf/2001/senn.pdf

Wald, A. (1950). Statistical Decision Functions. New York: Wiley.

Whitehead, J. (1997). The Design and Analysis of Sequential Medical Trials. Second edition. New York: Wiley.

Yin, Y. (2002). "Sample size calculation for a proof of concept study." Journal of Biopharmaceutical Statistics. 12, 267–276.

Zipfel, A. (2003). "Modeling the probability-cost-profitability architecture of portfolio management in the pharmaceutical industry." Drug Information Journal. 37, 185–205.